CAR T-Cell Therapy Recipients May Require Specialized COVID-19 Vaccine StrategiesNovember 3rd 2021
CAR T-cell therapies represent a potent treatment option for patients with heavily pretreated relapsed/refractory hematologic malignancies, however, the infection risk associated with treatment may hinder the efficacy of COVID-19 vaccines in this population.
New Drug Approvals Expand cGVHD Treatment Beyond Steroids, But Real-World Data Still NeededOctober 30th 2021
Ruxolitinib and belumosudil represent FDA-approved treatment options to manage cGVHD, however, real world data will determine best practices for treatment and future research directions within the space.
New Clinical Trial Will Assess Novel ADC in Drug Resistant HER2+ Breast CancerOctober 23rd 2021
The recently launched phase 2 ACE-Breast03 seeks to appraise the efficacy and safety of the novel antibody-drug conjugate, ARX788, in patients with metastatic HER2-positive breast cancer whose disease is resistant to previous targeted therapies.
Strategies That Combine Immunotherapies With Bevacizumab, Other Agents May Expand Utility of Immunotherapy in Recurrent Ovarian CancerOctober 10th 2021
Combining immunotherapy with other targeted therapies may result in more promising outcomes than immunotherapy alone in the treatment of recurrent ovarian cancer, according to an expert at University of California, Los Angeles.
Salvage Regorafenib Emphasizes Need for Nuanced Treatment Selection in Metastatic CRCOctober 9th 2021
An expert from The University of Texas MD Anderson Cancer Center recently highlighted the ramifications of the phase 2 ReDOS trial, the need for molecular profiling in mCRC, and ongoing research on the combination of TKIs and checkpoint inhibitors.
Expert Discusses Biggest Updates in NSCLC TreatmentOctober 1st 2021
“I think the biggest [change] that we’ve seen is the addition of adjuvant or consolidated chemotherapy following the completion of concurrent chemotherapy and radiation. We have seen the 4-year overall survival data now and the 5-year update from the PACIFIC study in the adjuvant setting, obviously confirming the initial signal that patients who have initiation of immunotherapy early carry a significant risk reduction for progression and overall survival…”
Cabozantinib Associated With Higher Rates of Certain AEs in Advanced Kidney CancerJune 11th 2021
While cabozantinib exposure was not a predictor of progression-free survival, it was related to high rate of palmar-plantar plantar erythrodysesthesia and diarrhea in patients with advanced renal cell carcinoma who are given frontline cabozantinib plus nivolumab.
Research Will Reveal Optimal Drug Sequencing in Pancreatic CancerApril 5th 2021
Optimizing first- and second-line therapy, understanding the role of maintenance therapy for patients with BRCA-positive disease, and developing improved therapeutic options for elderly patients has become a priority for research in metastatic pancreatic cancer.
Assessment Predicts Survival In Elderly Patients with DLBCLApril 2nd 2021
A simplified geriatric assessment offers a validated objective tool to assess fitness status and should be considered the new Elderly Prognostic Index standard to predict overall survival in older patients with diffuse large B-cell lymphoma.